Anti-L-selectin monoclonal antibodies (PDL BioPharma)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-L-selectin monoclonal antibodies (PDL BioPharma)

Drug Alias NameAnti-L-selectin monoclonal antibody DREG 200 - PDL BioPharmaDREG 200 - PDL BioPharmahDREG-200 - PDL BioPharmaSMART anti-L-selectin antibodiesAselizumab +[10]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionLeukocyte adhesion molecule-1 inhibitors

TargetsLeukocyte adhesion molecule-1

Therapy Area/IndicationsShockPsoriasisReperfusion Injury +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPdl Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPdl Biopharma Inc

Active IndicationsN/A

Inactive IndicationsShockPsoriasisReperfusion Injury +[5]

Other Information

ATC CodeN/A